Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

ClinicalTrials.gov ID: NCT07117487

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07117487. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Open-label Study to Evaluate Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 at Least 12 Months Following a Primary Dose of a Licensed Protein Subunit RSV Vaccine in Adult Participants ≥60 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.

Study identification

NCT ID
NCT07117487
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
ModernaTX, Inc.
Industry
Enrollment
507 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 5, 2025 (Actual)
Primary completion
Mar 27, 2026 (Actual)
Completion
Mar 27, 2026 (Actual)
Last update posted
May 4, 2026

2025 – 2026

United States locations

U.S. sites
11
U.S. states
11
U.S. cities
11
Facility City State ZIP Site status
Velocity Clinical Research, Denver Denver Colorado 80110 —
Indago Research & Health Center, Inc. Hialeah Florida 33012 —
Velocity Clinical Research, Savannah Savannah Georgia 31406 —
Velocity Clinical Research, Valparaiso Valparaiso Indiana 46383 —
Velocity Clinical Research, Covington Covington Louisiana 70433 —
Velocity Clinical Research, Rockville Rockville Maryland 20854 —
Velocity Clinical Research, Lincoln Lincoln Nebraska 68510 —
Velocity Clinical Research, Medford Medford Oregon 97504 —
Velocity Clinical Research, Austin Austin Texas 78759 —
Velocity Clinical Research, Hampton Hampton Virginia 23666 —
Velocity Clinical Research, Spokane Spokane Washington 99218 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07117487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.